Affiliation:
1. Department of Cardiology Clinical Sciences Lund University Skåne University Hospital Lund Sweden
2. Department of Cardiology Clinical Medicine Aalborg University Aalborg Denmark
3. Unit of Cardiology Department of Medicine Karolinska Institute Stockholm Sweden
4. Heart and Vascular Division Karolinska University Hospital Stockholm Sweden
5. Division of Cardiology Department of Clinical Science and Education Södersjukhuset Karolinska Institute Stockholm Sweden
6. Department of Clinical Science and Education Södersjukhuset Karolinska Institute Stockholm Sweden
7. Unit of Cardiology Capio S:t Göran Hospital Stockholm Sweden
Abstract
Background
The impact of baseline anemia in a contemporary acute coronary syndrome (
ACS
) population undergoing percutaneous coronary intervention in the era of predominant radial artery access, potent P2Y12 inhibition, and rare use of glycoprotein
II
b/
III
a inhibitors has not been adequately studied.
Methods and Results
ACS
patients who underwent percutaneous coronary intervention between 2014 and 2016 in the
VALIDATE
‐
SWEDEHEART
(Bivalirudin Versus Heparin in
ST
‐Segment and Non–
ST
‐Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies Registry) trial without missing values for hemoglobin were included (n=5482). Mortality, myocardial reinfarction, and major bleeding at 180 days were assessed using Cox regression models and propensity score matching. All studied comorbidities were more common in
ACS
patients who had anemia (n=792).
ACS
patients with anemia had higher rates of 180‐day mortality (6.9% versus 2.1%; hazard ratio, 1.9; 95%
CI
, 1.3–2.7;
P
<0.001), myocardial reinfarction (4.3% versus 1.9%; hazard ratio, 1.7; 95%
CI
, 1.1–2.7;
P
=0.013), and major bleeding (13.4% versus 8.2%; hazard ratio, 1.3; 95%
CI
, 1.0–1.6;
P
=0.041). The results were most evident in patients with a hemoglobin value <100 g/L, who had a nearly 10 times higher mortality rate.
Conclusions
Baseline anemia in
ACS
patients undergoing percutaneous coronary intervention, treated according to current practice including routine radial artery access, constitutes a high‐risk feature for both ischemic events, bleeding events, and mortality. A multidisciplinary approach is warranted to maximize benefit and minimize patient risk.
Clinical Trial Registration
URL
:
http://www.clinicaltrials.gov
. Unique identifier: NCT02311231.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献